A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.
Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.
Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC.